Atlas Venture Life Science Advisors’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-599,524	Closed	-$3.79M	–	17
2022 Q4	$3.79M	Hold	599,524	–	–	0.46%	13
2022 Q3	$3.07M	Hold	599,524	–	–	0.34%	14
2022 Q2	$3.75M	Hold	599,524	–	–	0.63%	14
2022 Q1	$2.13M	Hold	599,524	–	–	0.27%	15
2021 Q4	$3.01M	Buy	+599,524	New	+$3.62M	0.28%	14

Atlas Venture Life Science Advisors's FSTX Position: Q1 2023 in Review

Atlas Venture Life Science Advisors sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 599,524 shares — an estimated $3.79M sold.

Atlas Venture Life Science Advisors first reported a position in FSTX in Q4 2021 and held it in 5 quarters. The position peaked at $3.79M in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Atlas Venture Life Science Advisors reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 599,524 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.79M.
Atlas Venture Life Science Advisors first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Atlas Venture Life Science Advisors's F-star Therapeutics, Inc. Common Stock position peaked at $3.79M in Q4 2022.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2023, filed 15 May 2023.